CDXS,Codexis, Inc. | Healthcare - www.financetom.com

Healthcare

CDXS

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Codexis, Inc.CDXS

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Codexis, Inc. discovers, develops, and sells enzymes and other proteins.

The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening.

The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.

The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes.

It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency.

The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe.

The company was incorporated in 2002 and is headquartered in Redwood City, California.

Latest News >

Atlassian Insider Sold Shares Worth $1,470,592, According to a Recent SEC Filing

May 23, 2024

03:50 AM EDT, 05/23/2024 (MT Newswires) -- Michael Cannon-Brookes, 10% Owner, Director, Co-Chief Executive Officer, Co-Founder, on May 21, 2024, sold 8,241 shares in Atlassian ( TEAM ) for $1,470,592. Following the Form 4 filing with the SEC, Cannon-Brookes has control over a total of 209,871 shares of the company, with 209,871 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218024004333/xslF345X03/primarydocument.xml Price: 180.00, Change:...

Atlassian Insider Sold Shares Worth $1,470,591, According to a Recent SEC Filing

May 23, 2024

03:49 AM EDT, 05/23/2024 (MT Newswires) -- Scott Farquhar, 10% Owner, Director, Co-Chief Executive Officer, Co-Founder, on May 21, 2024, sold 8,241 shares in Atlassian ( TEAM ) for $1,470,591. Following the Form 4 filing with the SEC, Farquhar has control over a total of 209,871 shares of the company, with 209,871 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218024004332/xslF345X03/primarydocument.xml Price: 180.00, Change:...

Krystal Biotech Insider Sold Shares Worth $3,282,690, According to a Recent SEC Filing

May 23, 2024

03:49 AM EDT, 05/23/2024 (MT Newswires) -- Julian S Gangolli, Director, on May 20, 2024, sold 20,000 shares in Krystal Biotech ( KRYS ) for $3,282,690. SEC Filing: https://www.sec.gov/Archives/edgar/data/1711279/000153202324000008/xslF345X03/wk-form4_1716416222.xml Price: 172.69, Change: +3.44, Percent Change: +2.03 ...

Bitcoin (BTC) Price Rally, Dogecoin (DOGE) Advancement, Ripple (XRP) Predictions: Bits Recap May 23

May 23, 2024

TL;DR BTCs price climbed above $71,000 due to optimism about Ethereum ETF approval, resulting in a 6% weekly and 13% monthly increase, but then retraced to $69,500. DOGEs value ascended as well, briefly surpassing $0.17 and achieving a market cap near $25 billion. Significant metrics rose, with 85% of holders in profit. XRPs price saw a slight increase with predictions...